 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
LeMaitre Vascular, Inc. (LMAT) designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide.
The company provides angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; carotid shunts to temporarily divert or shut blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and powered phlebectomy devices that enable removal of varicose veins.
It also offers embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude blood flow; and perfusion catheters that temporarily perfuse blood and other liquids into the vasculature.
In addition, the company provides radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patients body, and allows them to locate tributaries or lesions beneath the skin; and remote endarterectomy devices to remove plaque from arteries in the leg.
Further, it offers valvulotomes that cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; vascular grafts to bypass or replace diseased arteries; vascular patches, which are used for precision endarterectomy vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and laparoscopic cholecystectomy devices to inject dye into the cystic duct during laparoscopic cholecystectomy, as well as laparoscopic accessory for use in laparoscopic gall bladder removal. LeMaitre Vascular, Inc. markets its products through direct and indirect sales force.
Shares have formed a bullish "flag" following the company's latest quarterly report. The medical device maker posted revenue of $25.8 million in the period, topping Street forecasts of $25.4 million. It reported EPS of 23 cents, above the 17c expected. The company expects full-year earnings to be 79 cents per share, with revenue expected to be $101.9 million. The company is presenting today at at the Canaccord Genuity 37th Annual Growth Conferencein Boston, MA. Higher share prices are expected for this stock..
52-Week Trading Range: $16.80 - $36.09
Entry Point: $33.00
Stop Loss: $31.35
Target Price: $36.30
LMAT closed at $36.68
